APA (7th ed.) Citation

EM, K., CD, M., MV, Z., E, D., CJ, F., JE, L., . . . HJ, R. (2026). Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: A target trial emulation in REPRIEVE. The lancet. HIV, 13(5), e306. https://doi.org/10.1016/S2352-3018(25)00354-6

Chicago Style (17th ed.) Citation

EM, Kileel, et al. "Risk of Obesity, Diabetes, Hypertension, and Major Adverse Cardiovascular Events After a Switch to an Integrase Inhibitor: A Target Trial Emulation in REPRIEVE." The Lancet. HIV 13, no. 5 (2026): e306. https://doi.org/10.1016/S2352-3018(25)00354-6.

MLA (9th ed.) Citation

EM, Kileel, et al. "Risk of Obesity, Diabetes, Hypertension, and Major Adverse Cardiovascular Events After a Switch to an Integrase Inhibitor: A Target Trial Emulation in REPRIEVE." The Lancet. HIV, vol. 13, no. 5, 2026, p. e306, https://doi.org/10.1016/S2352-3018(25)00354-6.